TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD)

Clinical trials for TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD) explained in plain language.

Never miss a new study

Get alerted when new TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD) trials appear

Sign up with your email to follow new studies for TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for stubborn lung infections that resist standard treatments

Disease control Completed

This study tested whether adding a drug called bedaquiline to standard antibiotics works better for adults with hard-to-treat MAC lung infections. Researchers compared bedaquiline against another standard drug in 129 participants over 24 weeks. The main goal was to see if the new…

Matched conditions: TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD)

Phase: PHASE2, PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD)

Get alerted when new TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX-LUNG DISEASE (MAC-LD) trials appear

New hope for stubborn lung infections that resist standard treatments